[The chrysotherapy of patients with Reiter's disease].
Chrisanol therapy was provided to 172 men suffering from Reiter's disease, having histocompatibility antigen B35 and its combination with B27 as well as B17 and B11 indicating that the articular syndrome may run a persistent and grave course. Chrisanol therapy brought about a decrease of the activity of complement, lysozyme, bactericidal activity of blood serum, a reduction of the content of serum IgG, and autoimmune reactions parameters. Chrisanol therapy was tolerated well. The ten-year follow-up revealed relapses in 8.3% of the patients.
Iu N
IuN
Kovalev
I I
II
Il'in
D000293:Adolescent; D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D016918:Arthritis, Reactive / Q000188:drug therapy*; D002908:Chronic Disease; D004112:Dimercaprol / Q000008:administration & dosage / Q000031:analogs & derivatives; D004341:Drug Evaluation; D006046:Gold / Q000008:administration & dosage; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D050607:Organogold Compounds; D009942:Organometallic Compounds / Q000008:administration & dosage; D020005:Propanols; D012008:Recurrence; D013438:Sulfhydryl Compounds
D018501:Antirheumatic Agents; D050607:Organogold Compounds; D009942:Organometallic Compounds; D020005:Propanols; D013438:Sulfhydryl Compounds; D004112:Dimercaprol; D006046:Gold; C013394:aurotioprol
Krizoterapiia bol'nykh bolezn'iu Reĭtera.